Charles River Laboratories International (CRL) ROE: History & Chart

Charles River Laboratories International, Inc.(CRL)

Medical - Diagnostics & Research · Wilmington, MA

$273.41+0.53 (+0.19%)

Delayed quote: Sep 16, 2026, 4:00 PM EDT

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA

19,000 employees

www.criver.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Birgit Girshick

View full financials

CRL Return on Equity (ROE) Metrics

RETURN ON EQUITY (ROE)

-8.40%

RETURN ON EQUITY (ROE) AVG TTM

-4.75%

RETURN ON EQUITY (ROE) AVG 3Y

4.04%

RETURN ON EQUITY (ROE) AVG 5Y

8.31%

RETURN ON EQUITY (ROE) AVG 10Y

15.29%

RETURN ON EQUITY (ROE) AVG 15Y

16.24%

RETURN ON EQUITY (ROE) AVG 20Y

12.22%

CURRENT VS TTM AVG

-76.76%

CURRENT VS 3Y AVG

-307.63%

CURRENT VS 5Y AVG

-201.06%

CURRENT VS 10Y AVG

-154.92%

CURRENT VS 15Y AVG

-151.72%

CURRENT VS 20Y AVG

-168.70%

SECTOR MEDIAN · HEALTHCARE

13.01%

median of 84 covered companies

CURRENT VS SECTOR MEDIAN

-164.55%

vs the sector median at left

NAME	MARKET CAP	RETURN ON EQUITY (ROE)	TTM	3Y	5Y
Charles River Laboratories International, Inc. (CRL)	$13.17B	-8.40%	-4.75%	4.04%	8.31%
Penumbra, Inc. (PEN)vs ›	$12.54B	10.49%	6.83%	5.29%	3.21%
DaVita Inc. (DVA)vs ›	$12.45B	N/A	329.18%	200.63%	164.66%
Encompass Health Corporation (EHC)vs ›	$12.29B	23.91%	22.63%	21.83%	21.13%
Tempus AI, Inc. (TEM)vs ›	$12.26B	-57.18%	-651.33%	-315.37%	-198.08%
Baxter International Inc. (BAX)vs ›	$12.16B	-17.13%	-12.46%	-8.76%	-1.37%
Exelixis, Inc. (EXEL)vs ›	$14.27B	46.68%	29.72%	22.87%	17.28%
Bio-Techne Corporation (TECH)vs ›	$11.32B	8.63%	6.23%	8.78%	10.01%
Universal Health Services, Inc. (UHS)vs ›	$10.97B	20.31%	18.80%	15.17%	15.31%
Solventum Corporation (SOLV)vs ›	$15.38B	29.88%	23.51%	17.50%	13.68%

NAME

MARKET CAP

RETURN ON EQUITY (ROE)

TTM

Charles River Laboratories International, Inc. (CRL)

$13.17B

-8.40%

-4.75%

4.04%

8.31%

Penumbra, Inc. (PEN)vs ›

$12.54B

10.49%

6.83%

5.29%

3.21%

DaVita Inc. (DVA)vs ›

$12.45B

N/A

329.18%

200.63%

164.66%

Encompass Health Corporation (EHC)vs ›

$12.29B

23.91%

22.63%

21.83%

21.13%

Tempus AI, Inc. (TEM)vs ›

$12.26B

-57.18%

-651.33%

-315.37%

-198.08%

Baxter International Inc. (BAX)vs ›

$12.16B

-17.13%

-12.46%

-8.76%

-1.37%

Exelixis, Inc. (EXEL)vs ›

$14.27B

46.68%

29.72%

22.87%

17.28%

Bio-Techne Corporation (TECH)vs ›

$11.32B

8.63%

6.23%

8.78%

10.01%

Universal Health Services, Inc. (UHS)vs ›

$10.97B

20.31%

18.80%

15.17%

15.31%

Solventum Corporation (SOLV)vs ›

$15.38B

29.88%

23.51%

17.50%

13.68%

Return on Equity (ROE) FAQ

What is the return on equity (ROE) for Charles River Laboratories International, Inc. (CRL)?

The return on equity (ROE) for CRL stock is -8.40%.

Is Charles River Laboratories International, Inc.'s return on equity (ROE) high or low?

The return on equity (ROE) of -8.40% is 201% below its 5-year average of 8.31%, near the low end of its 5-year range (-8.40%–16.74%).

What is the TTM average return on equity (ROE) for Charles River Laboratories International, Inc. (CRL)?

The TTM average return on equity (ROE) for CRL stock is -4.75%.

What is the 3Y average return on equity (ROE) for Charles River Laboratories International, Inc. (CRL)?

The 3Y average return on equity (ROE) for CRL stock is 4.04%.

What is the 5Y average return on equity (ROE) for Charles River Laboratories International, Inc. (CRL)?

The 5Y average return on equity (ROE) for CRL stock is 8.31%.

What is the 10Y average return on equity (ROE) for Charles River Laboratories International, Inc. (CRL)?

The 10Y average return on equity (ROE) for CRL stock is 15.29%.

What is the 15Y average return on equity (ROE) for Charles River Laboratories International, Inc. (CRL)?

The 15Y average return on equity (ROE) for CRL stock is 16.24%.

What is the 20Y average return on equity (ROE) for Charles River Laboratories International, Inc. (CRL)?

The 20Y average return on equity (ROE) for CRL stock is 12.22%.

DATE	RETURN ON EQUITY (ROE)
2026-06-27	-8.40%
2026-03-28	-6.28%
2025-12-27	-4.56%
2025-09-27	-2.45%
2025-06-28	-2.06%
2025-03-29	-0.99%
2024-12-31	0.30%
2024-09-28	10.92%
2024-06-29	11.60%
2024-03-30	12.05%
2023-12-31	13.20%
2023-09-30	14.37%
2023-07-01	14.89%
2023-04-01	15.97%
2022-12-31	16.34%
2022-09-24	16.61%
2022-06-25	16.74%
2022-03-26	16.19%
2021-12-31	15.42%
2021-09-25	16.34%
2021-06-26	17.08%
2021-03-27	17.17%
2020-12-31	17.23%
2020-09-26	15.89%
2020-06-27	15.48%
2020-03-28	14.99%
2019-12-31	15.42%
2019-09-28	15.10%
2019-06-29	15.04%
2019-03-30	16.37%
2018-12-31	17.18%
2018-09-29	10.92%
2018-06-30	10.91%
2018-03-31	11.34%
2017-12-31	11.80%
2017-09-30	19.37%
2017-07-01	19.01%
2017-04-01	18.76%
2016-12-31	18.50%
2016-09-24	16.36%
2016-06-25	17.03%
2016-03-26	19.87%
2015-12-31	20.37%
2015-09-26	20.53%
2015-06-27	19.84%
2015-03-28	18.99%
2014-12-31	18.85%
2014-09-27	17.70%
2014-06-28	17.48%
2014-03-29	15.74%
2013-12-31	16.04%
2013-09-28	15.56%
2013-06-29	14.39%
2013-03-30	15.35%
2012-12-31	16.19%
2012-09-29	17.73%
2012-06-30	18.27%
2012-03-31	18.94%
2011-12-31	20.85%
2011-09-24	-48.23%
2011-06-25	-51.61%
2011-03-26	-57.33%
2010-12-31	-48.98%
2010-09-25	2.35%
2010-06-26	6.22%
2010-03-27	7.69%
2009-12-31	8.32%
2009-09-26	-41.88%
2009-06-27	-43.40%
2009-03-28	-44.49%
2008-12-31	-43.63%
2008-09-27	9.02%
2008-06-28	8.89%
2008-03-29	8.47%
2007-12-31	8.30%
2007-09-29	8.47%
2007-06-30	5.39%
2007-03-31	4.94%
2006-12-31	-3.50%
2006-09-30	-2.61%
2006-07-01	0.50%
2006-04-01	0.82%
2005-12-31	7.77%
2005-09-24	6.25%
2005-06-25	6.09%
2005-03-26	6.58%
2004-12-31	6.10%
2004-09-25	16.40%
2004-06-26	16.21%
2004-03-27	15.87%
2003-12-31	17.25%
2003-09-27	17.83%
2003-06-28	18.45%

DATE

RETURN ON EQUITY (ROE)

2026-06-27

-8.40%

2026-03-28

-6.28%

2025-12-27

-4.56%

2025-09-27

-2.45%

2025-06-28

-2.06%

2025-03-29

-0.99%

2024-12-31

0.30%

2024-09-28

10.92%

2024-06-29

11.60%

2024-03-30

12.05%

2023-12-31

13.20%

2023-09-30

14.37%

2023-07-01

14.89%

2023-04-01

15.97%

2022-12-31

16.34%

2022-09-24

16.61%

2022-06-25

16.74%

2022-03-26

16.19%

2021-12-31

15.42%

2021-09-25

16.34%

2021-06-26

17.08%

2021-03-27

17.17%

2020-12-31

17.23%

2020-09-26

15.89%

2020-06-27

15.48%

2020-03-28

14.99%

2019-12-31

15.42%

2019-09-28

15.10%

2019-06-29

15.04%

2019-03-30

16.37%

2018-12-31

17.18%

2018-09-29

10.92%

2018-06-30

10.91%

2018-03-31

11.34%

2017-12-31

11.80%

2017-09-30

19.37%

2017-07-01

19.01%

2017-04-01

18.76%

2016-12-31

18.50%

2016-09-24

16.36%

2016-06-25

17.03%

2016-03-26

19.87%

2015-12-31

20.37%

2015-09-26

20.53%

2015-06-27

19.84%

2015-03-28

18.99%

2014-12-31

18.85%

2014-09-27

17.70%

2014-06-28

17.48%

2014-03-29

15.74%

2013-12-31

16.04%

2013-09-28

15.56%

2013-06-29

14.39%

2013-03-30

15.35%

2012-12-31

16.19%

2012-09-29

17.73%

2012-06-30

18.27%

2012-03-31

18.94%

2011-12-31

20.85%

2011-09-24

-48.23%

2011-06-25

-51.61%

2011-03-26

-57.33%

2010-12-31

-48.98%

2010-09-25

2.35%

2010-06-26

6.22%

2010-03-27

7.69%

2009-12-31

8.32%

2009-09-26

-41.88%

2009-06-27

-43.40%

2009-03-28

-44.49%

2008-12-31

-43.63%

2008-09-27

9.02%

2008-06-28

8.89%

2008-03-29

8.47%

2007-12-31

8.30%

2007-09-29

8.47%

2007-06-30

5.39%

2007-03-31

4.94%

2006-12-31

-3.50%

2006-09-30

-2.61%

2006-07-01

0.50%

2006-04-01

0.82%

2005-12-31

7.77%

2005-09-24

6.25%

2005-06-25

6.09%

2005-03-26

6.58%

2004-12-31

6.10%

2004-09-25

16.40%

2004-06-26

16.21%

2004-03-27

15.87%

2003-12-31

17.25%

2003-09-27

17.83%

2003-06-28

18.45%

Return on Equity (ROE): -8.40%

CRL Return on Equity (ROE)

CRL Average Return on Equity (ROE) Chart

CRL Current vs Average Return on Equity (ROE) Chart

CRL Return on Equity (ROE) Metrics

CRL Competitors' Return on Equity (ROE)

Return Analysis

Return on Equity (ROE) Formula & Definition

Return on Equity (ROE) FAQ

CRL Return on Equity (ROE) History

Related Metrics